The progesterone receptor (PR) modulates estrogen receptors α (ERα) action in breast cancer; it is an upregulated target gene of ER, and its expression is dependent on estrogen. PR is also a valuable prognostic biomarker in breast cancer, especially in hormone-positive breast cancer. High expression of PR is more frequently observed in tumors with a better baseline prognosis (ie, luminal A) than tumors with a poor baseline prognosis (ie, luminal B). In the following review, we present the role of PR in breast cancer, including the genomic characteristics and pathways in breast cancer, PR and endocrine therapy. © 2022 Li et al.
Zhuo Li, Hongrui Wei, Siyan Li, Pei Wu, Xiaoyun Mao. The Role of Progesterone Receptors in Breast Cancer. Drug design, development and therapy. 2022;16:305-314
PMID: 35115765
View Full Text